Once you understand patent terms and regulatory exclusivity, the next step is designing a protection timeline for your product. This article shows how to combine US and EU rules, the EU Pharma Package, and development choices into a practical exclusivity map for your asset.

Patents may last 20 years on paper, but real market protection for a drug or biologic depends on how you combine patent terms, extensions, and US/EU regulatory exclusivity. This article explains the key building blocks in plain language for life sciences teams.

AI can accelerate discovery, but it can’t be the inventor. This guide explains how inventorship works in AI-assisted drug discovery, what can go wrong in real workflows, and how in-house teams can document human decision-making to protect patent enforceability and deal readiness.

In life sciences and advanced materials sector, IP due diligence is more than a legal formality; it’s central to valuation, deal viability, and long-term competitiveness. This article outlines a practical roadmap for investors and growth-stage companies to assess IP assets, FTO, risk, and strategy with the rigor these transactions demand.

Intellectual property is the foundation of biotech success. Discover how platform-driven IP strategies, licensing frameworks, and strategic collaborations can amplify valuation, attract investors, and accelerate commercialization. Learn how Hylton Rodic Law helps biotech innovators protect the science, structure the deal, and scale the business.